138 related articles for article (PubMed ID: 8160250)
1. Radioimmunoassay for 7-hydroxy metabolite of fluphenazine and its application to plasma level monitoring in schizophrenic patients treated long term with oral and depot fluphenazine.
Aravagiri M; Marder SR; Van Putten T; Hawes EM; McKay G; Midha KK
Ther Drug Monit; 1994 Feb; 16(1):21-9. PubMed ID: 8160250
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic monitoring of steady-state plasma levels of the N4'-oxide metabolite of fluphenazine in chronically treated schizophrenic patients determined by a specific and sensitive radioimmunoassay.
Aravagiri M; Marder SR; Van Putten T; Hawes EM; McKay G; Hubbard JW; Midha KK
Ther Drug Monit; 1990 May; 12(3):268-76. PubMed ID: 2349611
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunoassay for fluphenazine sulfoxide in human plasma.
Midha KK; Hawes EM; Hubbard JW; McKay G; Rauw G; Sardessai MS; Aravagiri M; Moore MD
J Pharmacol Methods; 1988 Mar; 19(1):63-74. PubMed ID: 3367650
[TBL] [Abstract][Full Text] [Related]
4. Clinical perspectives of some neuroleptics through development and application of their assays.
Midha KK; Marder SR; Jaworski TJ; McKay G; Hubbard JW; Hawes EM; Van Putten T; Wirshing WC; Aravagiri M
Ther Drug Monit; 1993 Jun; 15(3):179-89. PubMed ID: 8101398
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine.
Marder SR; Van Putten T; Aravagiri M; Hubbard JW; Hawes EM; McKay G; Midha KK
Psychopharmacol Bull; 1989; 25(3):479-82. PubMed ID: 2626520
[TBL] [Abstract][Full Text] [Related]
6. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
Wiles DH; Gelder MG
Br J Clin Pharmacol; 1979 Dec; 8(6):565-70. PubMed ID: 533577
[TBL] [Abstract][Full Text] [Related]
7. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
Wiles DH; Gelder MG
Adv Biochem Psychopharmacol; 1980; 24():599-602. PubMed ID: 7405678
[No Abstract] [Full Text] [Related]
8. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
9. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.
Miller RS; Peterson GM; McLean S; Westhead TT; Gillies P
J Clin Pharm Ther; 1995 Apr; 20(2):55-62. PubMed ID: 7650075
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
[TBL] [Abstract][Full Text] [Related]
11. The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.
Midha KK; Hubbard JW; Marder SR; Hawes EM; Van Putten T; McKay G; May PR
Psychopharmacology (Berl); 1987; 93(3):369-73. PubMed ID: 3124166
[TBL] [Abstract][Full Text] [Related]
12. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
[TBL] [Abstract][Full Text] [Related]
13. Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.
Viala A; Hou N; Ba B; Durand A; Dufour H; D'Agostino N; Berda C; Jørgensen A
Psychopharmacology (Berl); 1984; 83(2):147-50. PubMed ID: 6146995
[TBL] [Abstract][Full Text] [Related]
14. A highly sensitive and specific radioimmunoassay for quantitation of plasma fluphenazine.
Lo ES; Fein M; Hunter C; Suckow RF; Cooper TB
J Pharm Sci; 1988 Mar; 77(3):255-8. PubMed ID: 3373431
[TBL] [Abstract][Full Text] [Related]
15. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
Tune LE; Creese I; Coyle JT; Pearlson G; Snyder SH
Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
[TBL] [Abstract][Full Text] [Related]
16. Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients.
Van Putten T; Aravagiri M; Marder SR; Wirshing WC; Mintz J; Chabert N
Psychopharmacol Bull; 1991; 27(2):91-6. PubMed ID: 1924666
[TBL] [Abstract][Full Text] [Related]
17. Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.
Marder SR; Hawes EM; Van Putten T; Hubbard JW; McKay G; Mintz J; May PR; Midha KK
Psychopharmacology (Berl); 1986; 88(4):480-3. PubMed ID: 3085136
[TBL] [Abstract][Full Text] [Related]
18. Depot fluphenazine decanoate and enanthate for schizophrenia.
David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia.
Chang SS; Javaid JI; Dysken MW; Casper RC; Janicak PG; Davis JM
Psychopharmacology (Berl); 1985; 87(1):55-8. PubMed ID: 3933037
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity.
Soni SD; Wiles D; Schiff AA; Bamrah JS
Br J Psychiatry; 1988 Sep; 153():382-4. PubMed ID: 3250675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
